In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 101 to 125 of 442

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Dersimelagon for treating erythropoietic protoporphyria and X-linked protoporphyria in people 12 years and over [ID6160]	Technology appraisal guidance	TBC
Deuruxolitinib for treating severe alopecia areata ID6597	Technology appraisal guidance	8 October 2026
Deutetrabenazine for treating tardive dyskinesia ID6550	Technology appraisal guidance	TBC
Dexmedetomidine for treating agitation associated with bipolar disorder in people 18 to 75 years [TS ID 10725]	Technology appraisal guidance	TBC
Dexmedetomidine for treating agitation associated with schizophrenia TS ID 10726	Technology appraisal guidance	TBC
Diabetes in pregnancy: management from preconception to the postnatal period - Managing type 1 diabetes (T1D) using hybrid closed loops (update)	NICE guideline	TBC
Diabetic retinopathy - ruboxistaurin [ID382]	Technology appraisal guidance	TBC
Digital hearing aids (Provisional title)	Health technology evaluation	TBC
Digital platforms to support rehabilitation before or after primary elective hip or knee replacement surgery	Health technology evaluation	11 August 2026
Digital self-help for eating disorders: early value assessment	Health technology evaluation	TBC
Digital technologies delivering CBT for insomnia and insomnia symptoms (provisional title)	Health technology evaluation	TBC
Digital technologies for managing mild to moderate symptoms of hip or knee osteoarthritis: early-value assessment	Health technology evaluation	22 January 2026
Digital technologies for multidisciplinary weight management	Health technology evaluation	TBC
Digital technologies to support asthma self-management: early value assessment	Health technology evaluation	17 April 2026
Digital technologies to support smoking cessation in secondary care patients: early value assessment	Health technology evaluation	TBC
Domestic Abuse	NICE guideline	TBC
Domvanalimab with zimberelimab for untreated unresectable advanced gastric, gastro-oesophageal junction or oesophageal cancer [ID6606]	Technology appraisal guidance	TBC
Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]	Technology appraisal guidance	TBC
Donidalorsen for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6457]	Technology appraisal guidance	18 June 2026
Dostarlimab with chemotherapy for untreated and with niraparib for maintenance treatment of advanced non-mucinous epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6311]	Technology appraisal guidance	TBC
Dostarlimab with platinum-based chemotherapy for advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency [ID6415]	Technology appraisal guidance	15 January 2026
Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age [ID6484]	Highly specialised technology	TBC
Doxorubicin nanoparticles for previously treated advanced hepatocellular carcinoma [ID1314]	Technology appraisal guidance	TBC
Duchenne muscular dystrophy Care UK guideline on respiratory care in children and adults with DMD	NICE review	17 December 2025
Dupilumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils ID6235	Technology appraisal guidance	11 February 2026

Results per page

10
25
50
All